Insights from computational studies on the potential of natural compounds as inhibitors against SARS-CoV-2 spike omicron variant

References

• A. Al-Romaima, Y. Liao, J. Feng, X. Qin, and G. Qin, Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: A narrative review, J. Thorac. Dis. 12 (2020), pp. 6054–6069. doi:10.21037/jtd-20-1810.
   PubMed Web of Science ®Google Scholar
• C.C. Lai, T.P. Shih, W.C. Ko, H.J. Tang, and P.R. Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int. J. Antimicrob. Agents 55 (2020), pp. 105924. doi:10.1016/j.ijantimicag.2020.105924.
   PubMed Web of Science ®Google Scholar
• Coronavirus disease (COVID-19) situation reports; software available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• R. Yadav, J.K. Chaudhary, N. Jain, P.K. Chaudhary, S. Khanra, P. Dhamija, A. Sharma, A. Kumar, and S. Handu, Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19, Cells 10 (2021), pp. 821. doi:10.3390/cells10040821.
   PubMed Web of Science ®Google Scholar
• T. Shu, M. Huang, D. Wu, Y. Ren, X. Zhang, Y. Han, J. Mu, R. Wang, Y. Qiu, D.Y. Zhang, and X. Zhou, SARS-Coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts, Virol. Sin. 35 (2020), pp. 321–329. doi:10.1007/s12250-020-00242-1.
   PubMed Web of Science ®Google Scholar
• Z. Zhang, N. Nomura, Y. Muramoto, T. Ekimoto, T. Uemura, K. Liu, M. Yui, N. Kono, J. Aoki, M. Ikeguchi, T. Noda, S. Iwata, U. Ohto, and T. Shimizu, Structure of SARS-CoV-2 membrane protein essential for virus assembly, Nat. Commun. 131 (2022), pp. 1–12.
   Google Scholar
• F. Chaudhry, S. Lavandero, X. Xie, B. Sabharwal, Y.Y. Zheng, A. Correa, J. Narula, and P. Levy, Manipulation of ACE2 expression in COVID-19, Open Hear. 7 (2020), pp. e001424.
   PubMed Web of Science ®Google Scholar
• J. Luan, Y. Lu, X. Jin, and L. Zhang, Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection, Biochem. Biophys. Res. Commun. 526 (2020), pp. 165–169. doi:10.1016/j.bbrc.2020.03.047.
   PubMed Web of Science ®Google Scholar
• W.T. Harvey, A.M. Carabelli, B. Jackson, R.K. Gupta, E.C. Thomson, E.M. Harrison, C. Ludden, R. Reeve, A. Rambaut, S.J. Peacock, and D.L. Robertson, SARS-CoV-2 variants, spike mutations and immune escape, Nat. Rev. Microbiol. 19 (2021), pp. 409–424. doi:10.1038/s41579-021-00573-0.
   PubMed Web of Science ®Google Scholar
• C. Yi, X. Sun, Z. Ling, and B. Sun, Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape, Cell. Mol. Immunol. 2022 (2022), pp. 1–4.
   Google Scholar
• H.M. Mengist, A.J. Kombe Kombe, D. Mekonnen, A. Abebaw, M. Getachew, and T. Jin, Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity, Semin. Immunol. 55 (2021), pp. 101533. doi:10.1016/j.smim.2021.101533.
   PubMed Web of Science ®Google Scholar
• R. Zhou, H. Chen, J. Chen, X. Chen, Y. Wen, and L. Xu, Extract from astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway, BMC Complement. Altern. Med. 18 (2018), pp. 1–8. doi:10.1186/s12906-018-2148-2.
   PubMed Web of Science ®Google Scholar
• S.E. Greasley, S. Noell, O. Plotnikova, R.A. Ferre, W. Liu, B. Bolanos, K. Fennell, J. Nicki, T. Craig, Y. Zhu, A.E. Stewart, and C.M. Steppan, Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants, bioRxiv, (2022), pp. 2022.01.17.476556.
   Google Scholar
• J. Li, S. Lai, G.F. Gao, and W. Shi, The emergence, genomic diversity and global spread of SARS-CoV-2, Nature 600 (2021), pp. 408–418. doi:10.1038/s41586-021-04188-6.
   PubMed Web of Science ®Google Scholar
• H. Akkız, The biological functions and clinical significance of SARS-CoV-2 variants of corcern, Front. Med. P (2022), pp. 101972.
   Web of Science ®Google Scholar
• N.L. Miller, T. Clark, R. Raman, and R. Sasisekharan, Insights on the mutational landscape of the SARS-CoV-2 omicron variant receptor-binding domain, Cell Reports Med. 3 (2022), pp. 100527. doi:10.1016/j.xcrm.2022.100527.
   PubMedGoogle Scholar
• S. Qin, M. Cui, S. Sun, J. Zhou, Z. Du, Y. Cui, and H. Fan, Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant omicron (B.1.1.529), Zoonoses 1 (2021). doi:10.15212/ZOONOSES-2021-0024.
   Google Scholar
• P. Han, L. Li, S. Liu, Q. Wang, D. Zhang, Z. Xu, P. Han, X. Li, Q. Peng, C. Su, B. Huang, D. Li, R. Zhang, M. Tian, L. Fu, Y. Gao, X. Zhao, K. Liu, J. Qi, J. Qi, G.F. Gao, and P. Wang, Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2, Cell 185 (2022), pp. 630–640.e10. doi:10.1016/j.cell.2022.01.001.
   PubMed Web of Science ®Google Scholar
• M. Macchiagodena, M. Pagliai, and P. Procacci, Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease, J. Mol. Graph. Model. 110 (2022), pp. 108042. doi:10.1016/j.jmgm.2021.108042.
   PubMed Web of Science ®Google Scholar
• S. Ding, I. Ullah, S.Y. Gong, J.R. Grover, M. Mohammadi, Y. Chen, D. Vézina, G. Beaudoin-Bussières, V.T. Verma, G. Goyette, F. Gaudette, J. Richard, D. Yang, A.B. Smith, M. Pazgier, M. Côté, C. Abrams, P. Kumar, W. Mothes, P.D. Uchil, A. Finzi, and C. Baron, VE607 stabilizes SARS-CoV-2 spike in the “RBD-up” conformation and inhibits viral entry, iScience 25 (2022), pp. 104528. doi:10.1016/j.isci.2022.104528.
   PubMed Web of Science ®Google Scholar
• F. Mosquera-Yuqui, N. Lopez-Guerra, and E.A. Moncayo-Palacio, Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: Molecular docking and molecular dynamics simulations, J. Biomol. Struct. Dyn. 40 (2022), pp. 2010–2023. doi:10.1080/07391102.2020.1835716.
   PubMed Web of Science ®Google Scholar
• A. Alqethami, A.Y. Aldhebiani, and I. Teixidor-toneu, Medicinal plants used in Jeddah, Saudi Arabia : A gender perspective, J. Ethnopharmacol. 257 (2020), pp. 112899. doi:10.1016/j.jep.2020.112899.
   PubMed Web of Science ®Google Scholar
• J. Roshni, R. Vaishali, K. Ganesh, N. Dharani, K.J. Alzahrani, H.J. Banjer, A.H. Alghamdi, A. Theyab, S.S. Ahmed, and S. Patil, Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to omicron B.1.1.529, J. Infect. Public Health 15 (2022), pp. 662–669. doi:10.1016/j.jiph.2022.05.002.
   PubMed Web of Science ®Google Scholar
• G. Kumar Paul, S. Mahmud, A.A. Aldahish, M. Afroze, S. Biswas, S. Briti Ray Gupta, M. Hasan Razu, S. Zaman, M. Salah Uddin, M.H. Nahari, M. Merae Alshahrani, M. Abdul Rahman Alshahrani, M. Khan, and M. Abu Saleh, Computational screening and biochemical analysis of Pistacia integerrima and Pandanus odorifer plants to find effective inhibitors against Receptor-Binding Domain (RBD) of the spike protein of SARS-Cov-2, Arab. J. Chem. 15 (2022), pp. 103600. doi:10.1016/j.arabjc.2021.103600.
   PubMed Web of Science ®Google Scholar
• C.H. Kim, Anti–SARS-CoV-2 natural products as potentially therapeutic agents, Front. Pharmacol. 12 (2021), pp. 1015. doi:10.3389/fphar.2021.590509.
   Web of Science ®Google Scholar
• K. Gopinath, E.M. Jokinen, S.T. Kurkinen, and O.T. Pentikäinen, Screening of natural products targeting SARS-CoV-2–ACE2 receptor interface – A MixMD based HTVS pipeline, Front. Chem. 8 (2020), pp. 1084. doi:10.3389/fchem.2020.589769.
   Web of Science ®Google Scholar
• M. Nedyalkova, M. Vasighi, S. Sappati, A. Kumar, S. Madurga, and V. Simeonov, Inhibition ability of natural compounds on receptor-binding domain of SARS-CoV2: An in silico approach, Pharmaceuticals 14 (2021), pp. 1328. doi:10.3390/ph14121328.
   Web of Science ®Google Scholar
• P. Kar, N.R. Sharma, B. Singh, A. Sen, and A. Roy, Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation, J. Biomol. Struct. Dyn. 39 (2021), pp. 4774–4785. doi:10.1080/07391102.2020.1780947.
   PubMed Web of Science ®Google Scholar
• P. Kar, M.M. Saleh-E-In, N. Jaishee, A. Anandraj, E. Kormuth, B. Vellingiri, C. Angione, P.K.S.M. Rahman, S. Pillay, A. Sen, D. Naidoo, A. Roy, and Y.E. Choi, Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19, J. Cell. Biochem. 123 (2022), pp. 964–986. doi:10.1002/jcb.30243.
   PubMed Web of Science ®Google Scholar
• A. Mehmood, S. Nawab, Y. Wang, A. Chandra Kaushik, and D.Q. Wei, Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A medicinal chemistry approach, Comput. Biol. Med. 143 (2022), pp. 105235. doi:10.1016/j.compbiomed.2022.105235.
   PubMed Web of Science ®Google Scholar
• L.G. Ferreira, R.N. Dos Santos, G. Oliva, and A.D. Andricopulo, Molecular docking and structure-based drug design strategies, Molecules 20 (2015), pp. 13384–13421. doi:10.3390/molecules200713384.
   PubMed Web of Science ®Google Scholar
• G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des. 27 (2013), pp. 221–234. doi:10.1007/s10822-013-9644-8.
   PubMed Web of Science ®Google Scholar
• S.E. Omer, T.M. Ibrahim, O.A. Krar, A.M. Ali, A.A. Makki, W. Ibraheem, and A.A. Alzain, Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations, Biochem. Biophys. Rep. 29 (2022), pp. 101225. doi:10.1016/j.bbrep.2022.101225.
   PubMedGoogle Scholar
• R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz, Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem. 49 (2006), pp. 6177–6196. doi:10.1021/jm051256o.
   PubMed Web of Science ®Google Scholar
• A.A. Alzain, F.A. Elbadwi, and F.O. Alsamani, Discovery of novel TMPRSS2 inhibitors for COVID-19 using in silico fragment-based drug design, molecular docking, molecular dynamics, and quantum mechanics studies, Inf. Med. Unl. 29 (2022), pp. 100870.
   PubMedGoogle Scholar
• K.J. Bowers, D.E. Chow, H. Xu, R.O. Dror, M.P. Eastwood, B.A. Gregersen, J.L. Klepeis, I. Kolossvary, M.A. Moraes, F.D. Sacerdoti, J.K. Salmon, Y. Shan, and D.E. Shaw, Scalable algorithms for molecular dynamics simulations on commodity clusters, ACM/IEEE SC 2006 Conference (SC'06) (2007), pp. 43.
   Google Scholar
• H. Arya and M.S. Coumar, Chapter 4 - Lead Identification and Optimization, in The Design & Development of Novel Drugs and Vaccines, T.K. Bhatt and N.D. Nimesh, eds., Academic Press, 2021, pp. 31–63.
   Google Scholar
• D.E.V. Pires, T.L. Blundell, and D.B. Ascher, pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, J. Med. Chem. 58 (2015), pp. 4066–4072. doi:10.1021/acs.jmedchem.5b00104.
   PubMed Web of Science ®Google Scholar
• B. Kar, B. Dehury, M.K. Singh, S. Pati, and D. Bhattacharya, Identification of phytocompounds as newer antiviral drugs against COVID-19 through molecular docking and simulation based study, J. Mol. Graph. Model. 114 (2022), pp. 108192. doi:10.1016/j.jmgm.2022.108192.
   PubMed Web of Science ®Google Scholar
• A. Khan, H. Waris, M. Rafique, M. Suleman, A. Mohammad, S.S. Ali, T. Khan, Y. Waheed, C. Liao, and D.Q. Wei, The omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data, Int. J. Biol. Macromol. 200 (2022), pp. 438–448. doi:10.1016/j.ijbiomac.2022.01.059.
   PubMed Web of Science ®Google Scholar
• J. Ai, H. Zhang, Y. Zhang, K. Lin, Y. Zhang, J. Wu, Y. Wan, Y. Huang, J. Song, Z. Fu, H. Wang, J. Guo, N. Jiang, M. Fan, Y. Zhou, Y. Zhao, Q. Zhang, Q. Liu, J. Lv, P. Li, C. Qiu, and W. Zhang, Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost, Emerg. Microbes Infect. 11 (2022), pp. 337–343. doi:10.1080/22221751.2021.2022440.
   PubMed Web of Science ®Google Scholar
• M.D. Sacco, Y. Hu, M.V. Gongora, F. Meilleur, M.T. Kemp, X. Zhang, J. Wang, and Y. Chen, The P132H mutation in the main protease of omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition, Cell Res. 2022 (2022), pp. 1–3.
   Google Scholar
• D.R. Owen, C.M.N. Allerton, A.S. Anderson, L. Aschenbrenner, M. Avery, S. Berritt, B. Boras, R.D. Cardin, A. Carlo, K.J. Coffman, A. Dantonio, L. Di, H. Eng, R.A. Ferre, K.S. Gajiwala, S.A. Gibson, S.E. Greasley, B.L. Hurst, and E.P. Kadar, An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19, Science 374 (2021), pp. 1586–1593. doi:10.1126/science.abl4784.
   PubMed Web of Science ®Google Scholar
• I. Celik, R. Yadav, Z. Duzgun, S. Albogami, A.M.E.-S. Fatimawali, T. Bin Emran, T.E. Tallei, and T. Bin Emran, Interactions of the receptor binding domain of SARS-CoV-2 variants with hACE2: Insights from molecular docking analysis and molecular dynamic simulation, Biology 10 (2021), pp. 880. doi:10.3390/biology10090880.
   PubMedGoogle Scholar
• A. Khan, D.Q. Wei, K. Kousar, J. Abubaker, S. Ahmad, J. Ali, F. Al-Mulla, S.S. Ali, N. Nizam-Uddin, A.M. Sayaf, and A. Mohammad, Preliminary structural data revealed that the SARS-CoV-2 B.1.617 variant’s RBD binds to ACE2 receptor stronger than the wild type to enhance the infectivity, ChemBioChem 22 (2021), pp. 2641–2649. doi:10.1002/cbic.202100191.
   PubMed Web of Science ®Google Scholar
• B. Usadel, U. Schlüter, M. Mølhøj, M. Gipmans, R. Verma, J. Kossmann, W.D. Reiter, and M. Pauly, Identification and characterization of a UDP glucuronate4-epimerase in arabidopsis, FEBS Lett. 569 (2004), pp. 327–331. doi:10.1016/j.febslet.2004.06.005.
   PubMed Web of Science ®Google Scholar
• R. Vignesh, V. Velu, and S.M. Sureban, Could nutraceutical approaches possibly attenuate the cytokine storm in COVID-19 patients? Front. Cell. Infect. Microbiol. 11 (2021), pp. 320. doi:10.3389/fcimb.2021.667733.
   Web of Science ®Google Scholar
• M. Volino-Souza, G.V. de Oliveira, C.A. Conte-Junior, and T.S. Alvares, Covid-19 quarantine: Impact of lifestyle behaviors changes on endothelial function and possible protective effect of beetroot juice, Front. Nutr. 7 (2020), pp. 204. doi:10.3389/fnut.2020.582210.
   Web of Science ®Google Scholar
• A. Ganesan, The impact of natural products upon modern drug discovery, Curr. Opin. Chem. Biol. 12 (2008), pp. 306–317. doi:10.1016/j.cbpa.2008.03.016.
   PubMed Web of Science ®Google Scholar
• Y. Kapelyukh, C.J. Henderson, N. Scheer, A. Rode, and C.R. Wolf, Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 knockout mice, Drug Metab. Dispos. 47 (2019), pp. 907–918. doi:10.1124/dmd.119.087718.
   PubMed Web of Science ®Google Scholar
• E. Zeiger, The test that changed the world: The Ames test and the regulation of chemicals, Mutat. Res. Toxicol. Environ. Mutagen. 841 (2019), pp. 43–48. doi:10.1016/j.mrgentox.2019.05.007.
   PubMed Web of Science ®Google Scholar